(4R)-3-[2-(3-propan-2-yloxypropylamino)acetyl]-1,3-thiazolidine-4-carbonitrile;hydrochloride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4R)-3-[2-(3-propan-2-yloxypropylamino)acetyl]-1,3-thiazolidine-4-carbonitrile;hydrochloride
• 化学式: C12H22ClN3O2S
• 分子量: 307.84
• InChiKey: JDSPZABWSBJUJZ-RFVHGSKJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.24
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  90.7
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
  申请人：Guilford Pharmaceuticals, Inc.

  公开号：US20040152745A1

  公开（公告）日：2004-08-05

  The present invention provides the inhibitors of dipeptidyl peptidase IV based upon or including proline or similar moieties. The inhibitors are useful for treating various disorders, including those of the central nervous system and the prostate. Many of the inhibitors can be reversible, and can cross the blood-brain barrier. Methods of making and using the inhibitors and treatment methods also are provided.

  本发明提供了基于或包含脯氨酸或类似基团的二肽基肽酶IV抑制剂。这些抑制剂可用于治疗各种疾病，包括中枢神经系统和前列腺疾病。许多抑制剂可以是可逆的，并且可以穿过血脑屏障。还提供了制备和使用抑制剂以及治疗方法。
• DIPEPTIDYL PEPTIDASE IV INHIBITORS AND METHODS OF MAKING AND USING DIPEPTIDYL PEPTIDASE IV INHIBITORS
  申请人：GUILFORD PHARMACEUTICALS INC.

  公开号：EP1228061A1

  公开（公告）日：2002-08-07
• EP1228061A4
  申请人：——

  公开号：EP1228061A4

  公开（公告）日：2004-12-15
• US6110949A
  申请人：——

  公开号：US6110949A

  公开（公告）日：2000-08-29
• [EN] DIPEPTIDYL PEPTIDASE IV INHIBITORS AND METHODS OF MAKING AND USING DIPEPTIDYL PEPTIDASE IV INHIBITORS<br/>[FR] INHIBITEURS DE LA DIPEPTIDYL PEPTIDASE IV; METHODES DE FABRICATION ET D'UTILISATION DESDITS INHIBITEURS
  申请人：GUILFORD PHARM INC

  公开号：WO2001034594A1

  公开（公告）日：2001-05-17

  The present invention provides the inhibitors of dipeptidyl peptidase IV based upon or including proline or similar moieties. The inhibitors are useful for treating various disorders, including those of the central nervous system and the prostate. Many of the inhibitors can be reversible, and can cross the blood-brain barrier. Methods of making and using the inhibitors and treatment methods also are provided.